<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00348790</url>
  </required_header>
  <id_info>
    <org_study_id>NU 05C4</org_study_id>
    <secondary_id>STU00005338</secondary_id>
    <secondary_id>NU 05C4</secondary_id>
    <nct_id>NCT00348790</nct_id>
  </id_info>
  <brief_title>Vatalanib in Treating Patients With Recurrent or Progressive Meningioma</brief_title>
  <official_title>A Phase II Trial of PTK-787 in Recurrent or Progressive Meningiomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Northwestern University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Vatalanib may stop the growth of tumor cells by blocking blood flow to the tumor
      and by blocking some of the enzymes needed for cell growth.

      PURPOSE: This phase II trial is studying how well vatalanib works in treating patients with
      recurrent or progressive meningioma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  Determine the efficacy of vatalanib, in terms of radiographic improvement and clinical
           improvement, in patients with recurrent or progressive meningioma.

      Secondary

        -  Determine the 6-month progression-free survival of these patients.

        -  Describe the response rate and overall survival of these patients.

        -  Determine the safety of vatalanib in these patients.

        -  Correlate the response rates with expression of vascular endothelial growth factor,
           epidermal growth factor receptor, platelet-derived growth factor, and HER2.

        -  Develop exploratory data concerning surrogate markers of angiogenic activity in vivo
           using magnetic resonance perfusion.

      OUTLINE: Patients receive oral vatalanib twice daily on days 1-28. Courses repeat every 28
      days for 1 year in the absence of disease progression or unacceptable toxicity.

      After completion of study treatment, patients are followed for 1 year.

      PROJECTED ACCRUAL: A total of 25 patients will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2006</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">November 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients Who DID NOT Experience Disease Progression or Death by 6 Months After Starting Treatment.</measure>
    <time_frame>From the date the first patient began treatment until the date the last patient has disease progression, becomes deceased, or completes 6 months of treatment</time_frame>
    <description>Patients were assessed with imaging techniques (MRI) during screening/baseline and then every 2 months after starting treatment. Survival status and disease status were recorded. The number of patients who did not experience an event (defined as either death for any reason or progression of their disease) by 6 months after starting treatment were counted.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determine Efficacy (Radiographic and Clinical Improvement)</measure>
    <time_frame>At baseline, every 2 weeks for 2 months, then every 8 weeks while on treatment</time_frame>
    <description>Efficacy will be assessed by MRI scan and neurological exam upon study entry, every 2 weeks for 2 months, then every 8 weeks while on treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Describe the Response Rate and Overall Survival in This Patient Population</measure>
    <time_frame>Every 2 months for up to 1 year after study treatment</time_frame>
    <description>Response rate and overall survival will be assessed by MRI scan every 2 months while on study treatment and follow-up will be done at regularly scheduled office visits up to 1 year after discontinuation of study treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Correlate the Response Rates With Expression of Certain Types of Genes</measure>
    <time_frame>At the end of study treatment</time_frame>
    <description>Correlation of response rates with the expression of certain types of genes will be assessed by examining tissue samples taken from previous surgery and testing for certain genes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Determine the Safety of Vatalanib in Patients With Recurrent of Progressive Meningiomas</measure>
    <time_frame>Every week while on study treatment</time_frame>
    <description>Safety of vatalanib will be assessed by labs being done weekly</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Months Patients Survive After Being Treatment on the Study.</measure>
    <time_frame>From the date the first patient began treatment until the date the last patient became deceased.</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Develop Data Concerning Certain Genes That Cause Tumors to Grow New Blood Vessels</measure>
    <time_frame>MRI with MR Perfusion will be done before treatment and then every 2 months while on study treatment</time_frame>
    <description>Data concerning certain genes that cause tumors to grow new blood vessels will be examined by MRI scan with MR Perfusion done before treatment and then every 2 months while on study treatment</description>
  </other_outcome>
  <other_outcome>
    <measure>To Use the FACT BR Questionnaire to Measure Quality of Life</measure>
    <time_frame>At baseline and then every time an MRI is performed while on study treatment.</time_frame>
    <description>FACT BR questionnaire will be used to measure quality of life at baseline and then every time an MRI scan is performed while on study treatment</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Brain and Central Nervous System Tumors</condition>
  <condition>Sarcoma</condition>
  <arm_group>
    <arm_group_label>Vatalanib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be treated with 500 mg of vatalanib, administered orally, twice a day for 28 days (1 cycle). Patients will start at a dose of 250 mg twice a day and increase by 250 mg per day every 7 days until 500 mg twice a day is reached.
Patients who are responding may remain on study treatment for 12 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vatalanib</intervention_name>
    <arm_group_label>Vatalanib</arm_group_label>
    <other_name>PTK787</other_name>
    <other_name>ZK 222584</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically confirmed meningioma, including the following subtypes:

               -  Benign meningioma

               -  Malignant meningioma

                    -  Steroid dosage stable for ≥ 5 days

               -  Atypical meningiomas

               -  Hemangiopericytoma

          -  May or may not have neurofibromatosis (NF) type 1 or 2 disease

               -  Patients with a history of NF may have other stable CNS tumors, such as
                  schwannoma, acoustic neuroma, or ependymoma only if those lesions have been
                  stable for the past 6 months

          -  Progressive or recurrent disease by MRI or CT scan

               -  Prior radiotherapy allowed provided evidence of disease progression is documented
                  by positron emission tomography, thallium scanning, magnetic resonance
                  spectroscopy, or surgery to rule out radiation necrosis for patients treated with
                  radiosurgery

          -  Recent resection of recurrent or progressive tumor allowed provided both of the
             following criteria are met:

               -  At least 4 weeks since prior surgery and recovered

               -  Evaluable residual disease

        PATIENT CHARACTERISTICS:

          -  Karnofsky performance status 60-100%

          -  Life expectancy &gt; 12 weeks

          -  Absolute neutrophil count ≥ 2,000/mm³

          -  Platelet count ≥ 100,000/mm³

          -  Hemoglobin ≥ 10 g/dL (transfusion allowed)

          -  SGOT and SGPT &lt; 2 times upper limit of normal (ULN)

          -  Bilirubin ≤ 1.5 times ULN

          -  Creatinine &lt; 1.5 mg/dL

          -  Negative proteinuria dipstick OR total urinary protein ≤ 500 mg AND creatinine
             clearance ≥ 50 mL/min

          -  PT, INR, and PTT ≤ 1.5 times ULN

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception during and for up to 6 months after
             completion of study treatment

          -  No history of any other cancer except nonmelanoma skin cancer or carcinoma in situ of
             the cervix, unless in complete remission and off all therapy for that disease for ≥ 3
             years

          -  No disease that would obscure toxicity or dangerously alter drug metabolism

          -  No bleeding disorders

          -  No severe and/or uncontrolled medical conditions that would limit compliance with
             study requirements, including any of the following:

               -  Uncontrolled high blood pressure

               -  History of labile hypertension

               -  History of poor compliance with an antihypertensive regimen

               -  Unstable angina pectoris

               -  Symptomatic congestive heart failure

               -  Myocardial infarction within the past 6 months

               -  Serious uncontrolled cardiac arrhythmia

               -  Uncontrolled diabetes

               -  Active or uncontrolled infection

               -  Interstitial pneumonia or extensive and symptomatic interstitial fibrosis of the
                  lung

               -  Impairment of gastrointestinal (GI) function or GI disease that may significantly
                  alter the absorption of vatalanib (i.e., ulcerative disease, uncontrolled nausea,
                  vomiting, or diarrhea, malabsorption syndrome, bowel obstruction, or inability to
                  swallow tablets)

               -  QTc &gt; 450 (male) or &gt; 470 (female)

               -  Congenital or acquired long QTc syndrome

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics

          -  Recovered from prior therapy

          -  At least 4 weeks since prior radiotherapy, including external-beam radiotherapy,
             interstitial brachytherapy, or gamma-knife radiosurgery

          -  At least 4 weeks since prior investigational agents

          -  More than 4 weeks since prior cytotoxic therapy (6 weeks for nitrosoureas)

          -  More than 4 weeks since prior immunotherapy

          -  More than 2 weeks since prior noncytotoxic or biologic therapies

          -  At least 2 weeks since prior drugs that affect hepatic metabolism (steroids should be
             tapered off if not clinically indicated)

          -  At least 2 weeks since prior and no concurrent enzyme-inducing anticonvulsant drugs

          -  No prior antivascular endothelial growth factor therapy

          -  No other concurrent investigational agents or anticancer therapy (including
             chemotherapy, radiotherapy, hormonal therapy, or immunotherapy)

          -  No concurrent warfarin

          -  No concurrent grapefruit or grapefruit juice
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey J. Raizer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwestern University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hematology-Oncology Associates of Illinois</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611-2998</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Robert H. Lurie Comprehensive Cancer Center at Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611-3013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Cancer Center at University of Washington Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195-6043</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 5, 2006</study_first_submitted>
  <study_first_submitted_qc>July 5, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 6, 2006</study_first_posted>
  <results_first_submitted>October 21, 2014</results_first_submitted>
  <results_first_submitted_qc>October 21, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 27, 2014</results_first_posted>
  <last_update_submitted>October 21, 2014</last_update_submitted>
  <last_update_submitted_qc>October 21, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 27, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Northwestern University</investigator_affiliation>
    <investigator_full_name>Jeffrey Raizer</investigator_full_name>
    <investigator_title>Jeffrey Raizer, MD</investigator_title>
  </responsible_party>
  <keyword>adult grade I meningioma</keyword>
  <keyword>adult grade II meningioma</keyword>
  <keyword>adult grade III meningioma</keyword>
  <keyword>adult malignant hemangiopericytoma</keyword>
  <keyword>adult anaplastic meningioma</keyword>
  <keyword>adult papillary meningioma</keyword>
  <keyword>adult melanocytic lesion</keyword>
  <keyword>recurrent adult brain tumor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
    <mesh_term>Meningioma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vatalanib</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Vatalanib</title>
          <description>Patients will be treated with 500 mg of vatalanib, administered orally, twice a day for 28 days (1 cycle). Patients will start at a dose of 250 mg twice a day and increase by 250 mg per day every 7 days until 500 mg twice a day is reached.
Patients who are responding may remain on study treatment for 12 months.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Began Treatment</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Completed Treatment</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Disease progression</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Required surgery</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unable to travel to study site</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Vatalanib</title>
          <description>Patients will be treated with 500 mg of vatalanib, administered orally, twice a day for 28 days (1 cycle). Patients will start at a dose of 250 mg twice a day and increase by 250 mg per day every 7 days until 500 mg twice a day is reached.
Patients who are responding may remain on study treatment for 12 months.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="25"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>21-30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>31-40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>41-50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>51-60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>61-70 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>71-80</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>81-90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients Who DID NOT Experience Disease Progression or Death by 6 Months After Starting Treatment.</title>
        <description>Patients were assessed with imaging techniques (MRI) during screening/baseline and then every 2 months after starting treatment. Survival status and disease status were recorded. The number of patients who did not experience an event (defined as either death for any reason or progression of their disease) by 6 months after starting treatment were counted.</description>
        <time_frame>From the date the first patient began treatment until the date the last patient has disease progression, becomes deceased, or completes 6 months of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vatalanib</title>
            <description>Patients will be treated with 500 mg of vatalanib, administered orally, twice a day for 28 days (1 cycle). Patients will start at a dose of 250 mg twice a day and increase by 250 mg per day every 7 days until 500 mg twice a day is reached.
Patients who are responding may remain on study treatment for 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Who DID NOT Experience Disease Progression or Death by 6 Months After Starting Treatment.</title>
          <description>Patients were assessed with imaging techniques (MRI) during screening/baseline and then every 2 months after starting treatment. Survival status and disease status were recorded. The number of patients who did not experience an event (defined as either death for any reason or progression of their disease) by 6 months after starting treatment were counted.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Determine Efficacy (Radiographic and Clinical Improvement)</title>
        <description>Efficacy will be assessed by MRI scan and neurological exam upon study entry, every 2 weeks for 2 months, then every 8 weeks while on treatment</description>
        <time_frame>At baseline, every 2 weeks for 2 months, then every 8 weeks while on treatment</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Describe the Response Rate and Overall Survival in This Patient Population</title>
        <description>Response rate and overall survival will be assessed by MRI scan every 2 months while on study treatment and follow-up will be done at regularly scheduled office visits up to 1 year after discontinuation of study treatment.</description>
        <time_frame>Every 2 months for up to 1 year after study treatment</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Correlate the Response Rates With Expression of Certain Types of Genes</title>
        <description>Correlation of response rates with the expression of certain types of genes will be assessed by examining tissue samples taken from previous surgery and testing for certain genes</description>
        <time_frame>At the end of study treatment</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Develop Data Concerning Certain Genes That Cause Tumors to Grow New Blood Vessels</title>
        <description>Data concerning certain genes that cause tumors to grow new blood vessels will be examined by MRI scan with MR Perfusion done before treatment and then every 2 months while on study treatment</description>
        <time_frame>MRI with MR Perfusion will be done before treatment and then every 2 months while on study treatment</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>To Use the FACT BR Questionnaire to Measure Quality of Life</title>
        <description>FACT BR questionnaire will be used to measure quality of life at baseline and then every time an MRI scan is performed while on study treatment</description>
        <time_frame>At baseline and then every time an MRI is performed while on study treatment.</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Determine the Safety of Vatalanib in Patients With Recurrent of Progressive Meningiomas</title>
        <description>Safety of vatalanib will be assessed by labs being done weekly</description>
        <time_frame>Every week while on study treatment</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Months Patients Survive After Being Treatment on the Study.</title>
        <time_frame>From the date the first patient began treatment until the date the last patient became deceased.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vatalanib</title>
            <description>Patients will be treated with 500 mg of vatalanib, administered orally, twice a day for 28 days (1 cycle). Patients will start at a dose of 250 mg twice a day and increase by 250 mg per day every 7 days until 500 mg twice a day is reached.
Patients who are responding may remain on study treatment for 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Months Patients Survive After Being Treatment on the Study.</title>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.2" lower_limit="15" upper_limit="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Patients were assessed for adverse events every 2 weeks for the first 2 months, then every 4 weeks (monthly) while on treatment and up to 30 days after the final dose of study drug.</desc>
      <group_list>
        <group group_id="E1">
          <title>Vatalanib</title>
          <description>Patients will be treated with 500 mg of vatalanib, administered orally, twice a day for 28 days (1 cycle). Patients will start at a dose of 250 mg twice a day and increase by 250 mg per day every 7 days until 500 mg twice a day is reached.
Patients who are responding may remain on study treatment for 12 months.
vatalanib</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE version 3</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <description>Subject was admitted for elective craniotomy. Subject went into atrial fibrillation unrelated to study drug.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Jaw pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Scalp wound</sub_title>
                <description>Subject was admitted after falling with scalp wound. The injury was unrelated to study treatment.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Platelets</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>T wave abnormalities/changes</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Vision loss</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Transaminase</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Alkaline phosphatase</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Creatinine</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Hypomagnesemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Hypophosphatemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neuropathy: Sensory-facial</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Neuropathy - Motor</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Memory impairment</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Spasm</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hematuria</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombosis/embolism (vascular access-related)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jeffrey Raizer, MD</name_or_title>
      <organization>Northwestern University</organization>
      <phone>312-503-4724</phone>
      <email>jraizer@nmff.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

